Drug intelligence / Profile preview

somatropin + rosiglitazone

Development stage: Unknown
Lead developer: GSK
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Subcutaneous, Oral

Overview

Somatropin + rosiglitazone is a combination therapy that has been studied for treating HIV-associated abdominal obesity and insulin resistance. Somatropin (recombinant human growth hormone) reduces visceral adipose tissue (VAT) but can worsen glucose homeostasis, while rosiglitazone, a thiazolidinedione, improves insulin sensitivity. When combined, rosiglitazone abrogates the adverse effects of somatropin on insulin sensitivity and glucose tolerance while maintaining somatropin's beneficial effect on reducing visceral fat.

Other names: recombinant human growth hormone + rosiglitazonerhGH + rosiglitazone

Targets

GHR (Growth hormone receptor)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on somatropin + rosiglitazone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on somatropin + rosiglitazone.

Explore the full profile